Taiho Pharmaceutical
Subsidiary of Otsuka Holdings (4578)
Assets
(7 total)
7Total Assets
1Approved
5Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | FGFR (FGFR1/2/3/4)Small molecule | Biliary Tract Cancer Cholangiocarcinoma | |
| Phase 3 | HIF-2alphaSmall molecule | Renal Cell Carcinoma Clear Cell Renal Cell Carcinoma | |
| Phase 3 | METSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | CD73 (NT5E)Small molecule | Pancreatic Ductal Adenocarcinoma | |
| Phase 3 | Thymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)Small molecule | Non-Small Cell Lung CancerColorectal CancerGastric Cancer | |
| Phase 3 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1/2 | RETSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
December 2027 (1)
Est. primary completion 2027-12 · NCT05676931 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
CasdatifanPhase 3Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Est. primary completion 2028-04 · NCT07011719 · CT.gov ↗
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
US, FDA · FDA · Source ↗
Recent
12 November 2026Filing submittedZipalertinibTaiho completes the NDA for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion NSCLC
US, FDA · Source ↗
Cullinan Therapeutics and Taiho Oncology · Source ↗
28 April 2026Filing acceptedZipalertinibFDA accepts NDA for zipalertinib (previously treated EGFR ex20ins NSCLC)
US, FDA · Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics · Source ↗
Financial reports
No financial reports recorded.